Toolgen And Thermo Fisher Scientific (TMO) Sign License Agreement For CRISPR/Cas9 Genome Editing Technology

Tuesday, March 10, 2015

Source: BioSpace

ToolGen, Inc. (, KONEX:199800), a Korean biotechnology company with a focus in the genome editing space, and Thermo Fisher Scientific (,), the world leader in serving science, announced today an agreement under which ToolGen, Inc. will license its CRISPR/Cas9 intellectual property portfolio to Thermo Fisher Scientific.

“This license agreement, as part of Thermo Fisher Scientific’s larger strategy, underlines Thermo Fisher Scientific’s commitment to invest into further developing these genome editing technologies into groundbreaking products that enable our customers to make our world healthier, cleaner and safer.”

Thermo Fisher will utilize the technology to develop and market new CRISPR reagent kits, bringing new tools to researchers working in the rapidly growing field. The kits will augment Thermo Fisher’s strong portfolio in the complementary transcription activator-like effector nucleases (TALEN) technique.

Scientists have begun to use the CRISPR/Cas9 system, which was originally identified as part of the adaptive immune system of many bacterial species, for targeted genome engineering in eukaryotic cells. The licensed intellectual property is based, in part, on the discovery by Dr. Jin Soo Kim, a researcher at Seoul National University and co-founder of ToolGen, Inc., that the CRISPR/Cas9 system can be used to engineer cells found in multicellular organisms such as mammals, plants and fungi.

Under the terms of the agreement, Thermo Fisher Scientific is granted a worldwide license for research applications including the development and sale of reagents, cell lines, and animal models, as well as rights for high throughput screening, diagnostics, and bioproduction. Thermo Fisher Scientific also has the right to grant sublicenses in each of these fields. ToolGen retains its rights in broad areas including high throughput screening, diagnostics, bioproduction, plant biotechnology and gene/cell therapy.

View All News »